Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial



Summary

A Phase 1 clinical trial investigated the safety and feasibility of intracerebroventricular (ICV) administration of bivalent CAR T-cells targeting both EGFR and IL-13Rα2 in patients with recurrent glioblastoma (GBM). This “Author Correction” likely addresses an error or clarification within the original publication of this trial. The trial aimed to assess if these engineered T-cells, designed to recognize and destroy GBM cells expressing either EGFR or IL-13Rα2, could be safely delivered directly to the brain’s ventricles. The study represents a promising immunotherapy approach for treating this aggressive brain cancer, but the correction indicates a need to address a specific issue in the original publication.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!